Federica Sorà, Carmen Di Grazia, Patrizia Chiusolo, Anna Maria Raiola, Stefania Bregante, Nicola Mordini, Attilio Olivieri, Anna Paola Iori, Francesca Patriarca, Sigal Grisariu, Elisabetta Terruzzi, Alessandro Rambaldi, Simona Sica, Benedetto Bruno, Emanuele Angelucci, Andrea Bacigalupo,
This is a multicenter retrospective comparison of 2 myeloablative conditioning regimens in 454 patients with acute myeloid leukemia (AML) in remission: busulfan (4 days) and fludarabine (BUFLU) versus thiotepa, busulfan, and fludarabine (TBF). Eligible for this study were patients allografted between January 2008 and December 2018 in 10 transplant centers, with AML in first or second remission: 201 patients received BUFLU, whereas 253 received TBF. The 2 groups (BUFLU and TBF) were comparable for age ( ...
Tópico(s): Acute Lymphoblastic Leukemia research
2019 - Elsevier BV | Biology of Blood and Marrow Transplantation
Sebastian Giebel, Myriam Labopin, Małgorzata Sobczyk‐Kruszelnicka, Matthias Stelljes, Jenny Byrne, Nathalie Fegueux, Dietrich W. Beelen, Montserrat Rovira, Alexandros Spyridonidis, Didier Blaise, Martin Bornhäuser, Ìhsan Karadoǧan, Bipin N. Savani, Arnon Nagler, Mohamad Mohty, Sonja Martin, Patrice Chevallier, Andreas Neubauer, Gandhi Damaj, Yener Koç, Arnold Ganser, Matthew Collin, Ibrahim Yakoub‐Agha, Hakan Özdoğu, Mercedes Colorado Araujo, Maija Itälä‐Remes, Kim Orchard, Cecilia Isaksson, Wolfgang Bethge, Hans Martin, Mahmoud Aljurf, Edgar Faber, Dolores Caballero, Pavel Žák, Xavier Leleu, Jacques‐Olivier Bay, Pierre‐Simon Rohrlich, Nicolaus Kröger, Anne Huynh, Kerstin Schäfer‐Eckart, Nöel Milpied, Stig Lenhoff, Aloysius Ho, Jose Luis Bello López, Nicola Mordini, Bruno Lioure, Kazimierz Hałaburda, Attilio Olivieri, Tobias Gedde‐Dahl, Rachel Protheroe, Johanna Tischer, Matthias Klammer, Johannes Clausen, Victoria Potter, Marco Ladetto, Hervé Tilly, Éric Deconinck, Arne Brecht, Lutz Müller, Thomas Heinicke, Juan Pio Torres Carrete, Ali Bazarbachi, Péter Reményi, Marie Thérèse Rubio, Renato Fanin, José Antonio Pérez‐Simón, Murawski Niels, José L. Díez‐Martín, Mutlu Arat, Olivier Hermine, Gèrard Socié, Jan J. Cornelissen, Stella Santarone, D Guyotat, Claude‐Eric Bulabois, Paolo Bernasconi, Jan-Erik Johansson, Radovan Vrḫovac, Hildegard Greinix, José Luis López Lorenzo, Shashikant Apte, Charles Craddock, Guido Kobbe, Mohsen Al Zahrani, Peter Dreger, Andrzej Lange, Abdelghani Tbakhi, Ellen Meijer, Carlos Vallejo Llamas, Josep‐María Ribera, Paolo Corradini, Fabio Benedetti, Alessandro Rambaldi, Virginie Gandemer, Jean‐Valère Malfuson, Ain Kaare, Antonio M. Risitano, Mario Petrini, Carmine Selleri, Depei Wu,
Tópico(s): Acute Lymphoblastic Leukemia research
2020 - Springer Nature | Bone Marrow Transplantation
Patrizia Chiusolo, Gesine Bug, Attilio Olivieri, Mats Brune, Nicola Mordini, P Alessandrino, Alida Dominietto, Anna Maria Raiola, Carmen Di Grazia, Francesca Gualandi, Maria Teresa Van Lint, Felicetto Ferrara, Olimpia Finizio, Emanuele Angelucci, Andrea Bacigalupo,
Highlights•Favorable outcome of a modified PT-CY regimen, with cyclosporin given before PT-CY.•It is associated with a very low rate of relapse in remission patients.•We have seen a low incidence of GVHD, despite the use of cyclosporine before PT-CY.•These results may not translate automatically to unmanipulated peripheral blood.AbstractWe report a modified post-transplant cyclophosphamide (PT-CY) regimen, for unmanipulated haploidentical marrow transplants, in 150 patients with acute myeloid leukemia ( ...
Tópico(s): Acute Lymphoblastic Leukemia research
2018 - Elsevier BV | Biology of Blood and Marrow Transplantation
Attilio Olivieri, Michele Cimminiello, Paolo Corradini, Nicola Mordini, Roberta Fedele, Carmine Selleri, Francesco Onida, Francesca Patriarca, Enzo Pavone, Silvia Svegliati, Armando Gabrielli, Paola Bresciani, Roberta Nuccorini, Sara Pasquina Pascale, Sabrina Coluzzi, Fabrizio Pane, Antonella Poloni, Jacopo Olivieri, Pietro Leoni, Andrea Bacigalupo,
Key Points Efficacy of imatinib in steroid-refractory chronic GVHD was prospectively compared across 3 different response systems, with high agreement. Validity of quantitative-based assessment of response with NIH criteria was confirmed by its prognostic impact on long-term survival.
Tópico(s): Platelet Disorders and Treatments
2013 - Elsevier BV | Blood
Federica Sorà, Simona Sica, Carmen Di Grazia, Patrizia Chiusolo, Luca Laurenti, Nicola Mordini, Attilio Olivieri, Anna Paola Iori, Emanuele Angelucci, Andrea Bacigalupo,
Abstract INTRODUCTION The combination of Busulfan and fludarabine (BU-FLU) is considered a standard conditioning regimen for patients with acute myeloid leukemia undergoing an allogeneic hemopoietic stem cell transplant (HSCT) , especially in patient older than 40 years of age. However, in a recent prospective study, designed for patients in first or second remission (CR1 or CR2) the incidence of leukemia relapse at 3 years was 38%, both for patients receiving BU-FLU as well as for patients randomized ...
Tópico(s): Chronic Myeloid Leukemia Treatments
2017 - Elsevier BV | Blood
Denise Wareham, Shirley Hudson, M. Ellis, Lara Rowley, Daja Barton, Erwin T. Janssen, Jessy Lardon, Jo Dierick, Pierre Zachée, Ka Wu, L. Katzir, Rasha Ashkar, Orna Ben, Gila Hyams, Tsila Zuckerman, Johan Lasse, Jørn Thue, Yngvar Kristiansen, Tobias Fløisand, Dominique Issarni, Steven Le Gouill, Efstathia Sarla, Konstantinos Gkontopoulos, Konstantinos Gkirkas, Panagiotis Tsirigotis, Laura Orlando, Francesca Patriarca, Stefano Botti, Iris Agreiter, Francesca Bonifazi, Nicola Mordini, Attilio Bondanza, Roberto Crocchiolo, Gianpaolo Gargiulo, Dawn Collier, George Trandafir, Laura Tipler, Wai Keong Wong, Annabel McMillan, Hebah Ali,
Background: Sibling donors remain an important source of haematopoietic stem cells for allogeneic transplantation.Family dynamics are both complex and diverse and we must be mindful of this when considering potential sibling donors (PSDs).Methods: In Oxford, we have developed a donor-centered protocol that supports and respects the privacy of PSDs whilst recognising their freedom of choice and maintaining the JACIE Standards.The protocol was developed in response to a PSD complaint.Results: Initially, ...
Tópico(s): Polyomavirus and related diseases
2018 - Springer Nature | Bone Marrow Transplantation
Corrado Girmenia, Anna Maria Raiola, Alfonso Piciocchi, Alessandra Algarotti, Marta Stanzani, Laura Cudillo, Clara Pecoraro, Stefano Guidi, Anna Paola Iori, Barbara Montante, Patrizia Chiusolo, Edoardo Lanino, Angelo Michele Carella, Elisa Zucchetti, Benedetto Bruno, Giuseppe Irrera, Francesca Patriarca, D Baronciani, Maurizio Musso, Arcangelo Prete, Antonio M. Risitano, Domenico Russo, Nicola Mordini, Domenico Pastore, Adriana Vacca, Francesco Onida, Sadia Falcioni, Giovanni Pisapia, Giuseppe Milone, Daniele Vallisa, Attilio Olivieri, Alessandro Bonini, Elio Castagnola, Simona Sica, Ignazio Majolino, Alberto Bosi, Alessandro Busca, William Arcese, Giuseppe Bandini, Andrea Bacigalupo, Alessandro Rambaldi, Anna Locasciulli,
Epidemiologic investigation of invasive fungal diseases (IFDs) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be useful to identify subpopulations who might benefit from targeted treatment strategies. The Gruppo Italiano Trapianto Midollo Osseo (GITMO) prospectively registered data on 1858 consecutive patients undergoing allo-HSCT between 2008 and 2010. Logistic regression analysis was performed to identify risk factors for proven/probable IFD (PP-IFD) during the early (days 0 ...
Tópico(s): Infectious Diseases and Mycology
2014 - Elsevier BV | Biology of Blood and Marrow Transplantation
Attilio Olivieri, Franco Locatelli, Marco Zecca, Adele Sanna, Michele Cimminiello, Roberto Raimondi, Guido Gini, Nicola Mordini, Adriana Balduzzi, Pietro Leoni, Armando Gabrielli, Andrea Bacigalupo,
Abstract We previously reported that patients with fibrotic, chronic graft-versus-host disease (cGVHD) have antibodies activating the platelet-derived growth factor receptor pathway. Because this pathway can be inhibited by imatinib, we performed a pilot study including 19 patients with refractory cGVHD, given imatinib at a starting dose of 100 mg per day. All patients had active cGVHD with measurable involvement of skin or other districts and had previously failed at least 2 treatment lines. Patient ...
Tópico(s): Eosinophilic Disorders and Syndromes
2009 - Elsevier BV | Blood
Elena Rostagno, Anna Campanati, Nicola Mordini, Chiara Cannici, Marco Cioce, Valentina De Cecco, Emanuela Samarani, Robin Foà, Attilio Olivieri, Stefano Botti,
Abstract Skin is usually the first and most affected organ involved in graft‐versus‐host disease (GvHD), and treatment is still a clinical challenge. Although the need for skin‐directed treatments such as physical treatments and topical medications are generally agreed on, what the gold standard treatment strategy should be remains open to debate. The aim of this scoping review was to synthesize the current knowledge on the topical and physical treatments of cutaneous GvHD in haematopoietic stem ...
Tópico(s): Immunotherapy and Immune Responses
2022 - Wiley | Journal of the European Academy of Dermatology and Venereology
Corrado Girmenia, Gian María Rossolini, Alfonso Piciocchi, Alice Bertaina, Giovanni Pisapia, Domenico Pastore, Simona Sica, Alessandro Severino, Laura Cudillo, Fabio Ciceri, Rosanna Scimè, Letizia Lombardini, Claudio Viscoli, Alessandro Rambaldi, Marco Frigeni, Alessandro Rambaldi, Consuelo Corti, Fabio Ciceri, Gabriella Mometto, C. Annaloro, Erminia Casari, Luca Castagna, Giuseppe Rossi, Chiara Cattaneo, Domenico Russo, Valeria Cancelli, Emilio Paolo Alessandrino, Francesco Ripamonti, Fabio Pavan, Attilio Rovelli, Clara Pecoraro, Alessandro Busca, Francesca Carraro, Franca Fagioli, Susanna Gallo, Daniele Caravelli, Marco De Gobbi, Giuseppe Saglio, Claudia Castellino, Nicola Mordini, Gianluca Gaïdano, Luca Nassi, Roberto Raimondi, Michele Vespignani, Anna Maria Scattolin, Irene Sara Panizzolo, Simone Cesaro, Anna Candoni, Francesca Patriarca, Andrea Bacigalupo, Anna Maria Raiola, Elio Castagnola, Edoardo Lanino, Marta Stanzani, Giuseppe Bandini, Erika Massaccesi, Arcangelo Prete, Simona Bassi, Daniele Vallisa, Cecilia Caramatti, Franco Aversa, Eliana Zuffa, Stefano Guidi, Alberto Bosi, Veronica Tintori, Anna Paola Iori, Saveria Capria, Laura Cudillo, William Arcese, Teresa Dentamaro, Paolo de Fabritiis, Barbara Anaclerico, Anna Chierichini, Monica Piedimonte, Antonella Ferrari, Francesco Marchesi, Andrea Mengarelli, Elisabetta Cerchiara, Maria Cristina Tirindelli, Javid Gaziev, Alessandro Severino, Ignazio Majolino, Patrizia Chiusolo, Simona Sica, Alice Bertaina, Barbarella Lucarelli, Maria Speranza Massei, Alessandra Carotti, Katia Perruccio, Maurizio Caniglia, Stella Santarone, Paolo Di Bartolomeo, Serena Mazzotta, Piero Galieni, Attilio Olivieri, Gennaro De Rosa, Antonio M. Risitano, Mario Delia, Giorgina Specchia, Giulia Palazzo, Giovanni Pisapia, Giuseppe Messina, Giuseppe Irrera, Emanuele Angelucci, D Baronciani, Adriana Vacca, Alessandra Crescimanno, Maurizio Musso, Rosanna Scimè, Alida Imbriani, Giuseppe Milone,
Infections by carbapenem-resistant Klebsiella pneumoniae (CRKp) represent a challenging problem after SCT. A retrospective survey (January 2010 to July 2013) involving 52 Italian centers was performed to assess the epidemiology and the prognostic factors of CRKp infections in auto- and allo-SCT. Cases of CRKp infection were reported in 53.4% of centers. CRKp infections were documented in 25 auto-SCTs and 87 allo-SCTs, with an incidence of 0.4% (from 0.1% in 2010 to 0.7% in 2013) and 2% (from 0.4% in ...
Tópico(s): Pneumonia and Respiratory Infections
2014 - Springer Nature | Bone Marrow Transplantation
Domenico Russo, Nicola Polverelli, Michele Malagola, Mirko Farina, Alessandro Leoni, Simona Bernardi, Sonia Mammoliti, Nicoletta Sacchi, Massimo Martino, Fabio Ciceri, Francesco Zallio, Attilio Olivieri, Sadia Falcioni, Gabriella Storti, Mariagrazia Michieli, Paola Carluccio, Anna Grassi, Elena Oldani, Francesca Bonifazi, Arcangelo Prete, Irene Cavattoni, Marianna Maffeis, Domenico Pastore, Adriana Vacca, Daniela Caravelli, M Mirabile, Nicola Mordini, Chiara Nozzoli, Maura Faraci, Vincenzo Federico, Sonia Ronconi, Cristina Skert, Francesco Onida, Magda Marcatti, Simona Piemontese, Franco Narni, Adriana Balduzzi, Giuseppina De Simone, Alessandra Picardi, Marco De Gobbi, Elisabetta Calore, Stefania Tringali, Marco Zecca, Simona Secondino, Barbara Guiducci, Matteo Pelosini, Eliana Zuffa, Luca Facchini, Manuela Imola, Anna Paola Iori, Anna Proia, Simona Sica, Daniele Armiento, Angelo Michele Carella, Chiara Maria Dellacasa, Franca Fagioli, Marco Rabusin, Andrea Ferrario, Francesca Elice,
The Transplant Centers belonging to Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO) conducted a survey with the aim of evaluating the effect of SARS-CoV2 pandemic on the allogeneic transplant activity in Italy. The pandemic period from 1/3/2020 to 31/7/2020 was compared with the same period in 2019. Overall, in 2020 there was a 2.4% reduction in the number of allo-HCT cases compared to 2019. Interestingly, this deflection did not affect the acute leukemia cases (+5.7% in 2020). The use of ...
Tópico(s): Hematopoietic Stem Cell Transplantation
2021 - Springer Nature | Bone Marrow Transplantation
Attilio Olivieri, Michele Cimminiello, Franco Locatelli, Marco Zecca, Paolo Corradini, Francesca Patriarca, Nicola Mordini, Pasquale Iacopino, Amedea Donelli, Carmine Selleri, Manuela Badiali, Giovanna Lucchini, Guido Gini, Pietro Leoni, Alberto Bosi, Andrea Bacigalupo,
Tópico(s): Myeloproliferative Neoplasms: Diagnosis and Treatment
2010 - Elsevier BV | Blood
Corrado Girmenia, Alice Bertaina, Alfonso Piciocchi, Katia Perruccio, Alessandra Algarotti, Alessandro Busca, Chiara Cattaneo, Anna Maria Raiola, Stefano Guidi, Anna Paola Iori, Anna Candoni, Giuseppe Irrera, Giuseppe Milone, G. Marcacci, Rosanna Scimè, Maurizio Musso, Laura Cudillo, Simona Sica, Luca Castagna, Paolo Corradini, Francesco Marchesi, Domenico Pastore, Emilio Paolo Alessandrino, C. Annaloro, Fabio Ciceri, Stella Santarone, Luca Nassi, Claudio Farina, Claudio Viscoli, Gian María Rossolini, Francesca Bonifazi, Alessandro Rambaldi, Saveria Capria, Alice Bertaina, Angela Mastronuzzi, Daria Pagliara, Paola Bernaschi, Lucia Amico, Alessandra Carotti, Antonella Mencacci, Alessandro Busca, Benedetto Bruno, Cristina Costa, Angela Passi, G Ravizzola, Emanuele Angelucci, Anna Marchese, Patrizia Pecile, Anna Candoni, Giovanna Ventura, Renato Fanin, Claudio Scarparo, Angelo Pasquale Barbaro, Giuseppe Milone, Salvatore Leotta, Anna Marchese, G. Marcacci, Cristina Becchimanzi, Daniela Donnarumma, Stefania Tringali, Maria Teresa Baldi, Renato Scalone, Maria Teresa Baldi, Laura Cudillo, Alessandra Picardi, William Arcese, Carla Fontana, Simona Sica, Sabrina Giammarco, Teresa Spanu, Luca Castagna, Roberto Crocchiolo, Erminia Casari, Paolo Corradini, Alberto Mussetti, Eutilia Conte, Fabrizio Ensoli, G. Miragliotta, P. Marone, Milena Arghittu, Raffaella Greco, Alessandra Forcina, Paola Chichero, Stella Santarone, Paolo Di Bartolomeo, Paolo Fazii, Vesselina Kroumova, Nunzia Decembrino, Marco Zecca, P. Marone, Giovanni Pisapia, Giulia Palazzo, Giulia Palazzo, Edoardo Lanino, Maura Faraci, Elio Castagnola, Roberto Bandettini, Rocco Pastano, Simona Sammassimo, Rita Passerini, Piero Maria Stefani, Filíppo Gherlinzoni, Roberto Rigoli, Lucia Prezioso, Benedetta Cambò, Adriana Calderaro, Angelo Michele Carella, Nicola Cascavilla, Maria Labonia, Ivana Celeghini, Nicola Mordini, Federica Piana, Adriana Vacca, Marco Sanna, Giovanni Podda, Maria Teresa Corsetti, Andrea Rocchetti, Daniela Cilloni, Marco De Gobbi, Ornella Bianco, Franca Fagioli, Francesca Carraro, Gianfranco De Intinis, Alessandro Severino, Anna Proia, Gabriella Parisi, Daniele Vallisa, Massimo Confalonieri, Domenico Russo, Michele Malagola, G Ravizzola, Piero Galieni, Sadia Falcioni, Valeria Travaglini, Roberto Raimondi, Carlo Borghero, Giacomina Pavan, Arcangelo Prete, Tamara Belotti, Simone Ambretti, Manuela Imola, Anna Maria Mianulli, Maria Federica Pedna, Simone Cesaro, Giuliana Lo Cascio, Antonella Ferrari, Monica Piedimonte, Iolanda Santino, Monica Calandrelli, Attilio Olivieri, Francesca Orecchioni, M Mirabile, Riccardo Centurioni, Luciana Gironacci, Daniela Caravelli, Susanna Gallo, Marco Filippi, Luca Cupelli, Teresa Dentamaro, Silvana Falco, Ospedale S Eugenio, Serena Marotta, Antonio M. Risitano, Dora Lula, Pellegrino Musto, Giuseppe Pietrantuono, Antonio Traficante, Elisabetta Cerchiara, Maria Cristina Tirindelli, Giordano Dicuonzo, Anna Chierichini, Barbara Anaclerico, P Placanica,
Gram-negative bacteremia (GNB) is a major cause of illness and death after hematopoietic stem cell transplantation (HSCT), and updated epidemiological investigation is advisable.We prospectively evaluated the epidemiology of pre-engraftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs (auto-HSCTs) among 54 transplant centers during 2014 (SIGNB-GITMO-AMCLI study). Using logistic regression methods. we identified risk factors for GNB and evaluated the impact of GNB on the 4-month ...
Tópico(s): Mycobacterium research and diagnosis
2017 - Oxford University Press | Clinical Infectious Diseases
Attilio Olivieri, Giorgia Mancini, Jacopo Olivieri, Elena Marinelli Busilacchi, Michele Cimminiello, Sara Pasquina Pascale, Roberta Nuccorini, Francesca Patriarca, Paolo Corradini, Andrea Bacigalupo, Stefano Angelini, Antonella Poloni, Giovanni Grillo, Francesco Onida, Massimo Martino, Nicola Di Renzo, Arnon Nagler, Nicola Mordini, Benedetto Bruno, Fabio Ciceri, Francesca Bonifazi,
Tópico(s): PI3K/AKT/mTOR signaling in cancer
2020 - Springer Nature | Bone Marrow Transplantation
Anna Maria Raiola, Benedetto Bruno, Antonio M. Risitano, Federico Mosna, Irene Cavattoni, Francesco Onida, Giorgia Saporiti, Francesca Patriarca, Marta Lisa Battista, Vincenzo Pavone, Anna Mele, Patrizia Chiusolo, Simona Sica, Barbara Loteta, Carmen Di Grazia, Angelo Michele Carella, Dalila Salvatore, Enrico Morello, Alessandro Leoni, Luisa Giaccone, Paolo Bernasconi, Elisabetta Terruzzi, Nicola Mordini, Carlo Borghero, Francesco Zallio, Mario Luppi, A. Grassi, Attilio Olivieri, Eugenia Piras, Nicoletta Sacchi, Giovannino Ciccone, Anna Castiglione, Eliana Degrandi, Emanuele Angelucci, Massimo Martino, Francesca Bonifazi,
Tópico(s): Acute Lymphoblastic Leukemia research
2025 - Elsevier BV | Blood Advances
Patrizia Chiusolo, Gesine Bug, Attilio Olivieri, Brune Mats, Nicola Mordini, Emilio Paolo Alessandrino, Alida Dominietto, Anna Maria Raiola, Carmen Di Grazia, Francesca Gualandi, Maria Teresa Van Lint, Emanuele Angelucci, Andrea Bacigalupo,
Abstract Background. Haploidentical bone marrow transplantation (HAPLO-BMT) with post-transplant cyclophosphamide (PT-CY) is being increasingly used in patients with acute myeloid leukemia (AML) who lack a suitable HLA-matched donor. The standard Baltimore regimen calls for PT-CY 50 mg/kg on days +3 and +4, with a calcineurin inhibitor and mycophenolate (MMF) starting on day +5 after transplant. Aim of the study. We have modified the original Baltimore regimen (BBMT 2013; 19:117), and are now reporting ...
Tópico(s): Neutropenia and Cancer Infections
2016 - Elsevier BV | Blood
Luisa Giaccone, Giorgia Mancini, Nicola Mordini, Gaetano Gargiulo, Valentina De Cecco, Stefano Angelini, Mario Arpinati, D Baronciani, Valentina Bozzoli, Stéfania Bramanti, E Calore, Irene Cavattoni, Michele Cimminiello, A. Colombo, Luca Facchini, Sadia Falcioni, Maura Faraci, Roberta Fedele, S. Guidi, Anna Paola Iori, Serena Marotta, Maria Caterina Micò, Giuseppe Milone, Francesco Onida, Domenico Pastore, Francesca Patriarca, Massimo Pini, Roberto Raimondi, Attilio Rovelli, Stella Santarone, Antônio Generoso Severino, Cristina Skert, Maria Teresa Lupo Stanghellini, Cristina Tecchio, E Vassallo, Martina Chiarucci, Benedetto Bruno, Francesca Bonifazi, Attilio Olivieri,
Several guidelines have been published about management of chronic GvHD (cGvHD), but the clinical practice still remains demanding. The Gruppo Italiano Trapianto di Midollo Osseo (GITMO) has planned a prospective observational study on cGvHD, supported by a dedicated software, including the updated recommendations. In view of this study, two surveys have been conducted, focusing the management of cGvHD and ancillary therapy in cGvHD, to address the current 'real life' situation. The two surveys were ...
Tópico(s): Pituitary Gland Disorders and Treatments
2017 - Springer Nature | Bone Marrow Transplantation
Attilio Olivieri, Michele Cimminiello, Paolo Corradini, Pasquale Iacopino, Amedea Donelli, Nicola Mordini, Carmine Selleri, Vincenzo Pavone, Renato Fanin, Franco Locatelli, Andrea Bacigalupo, Alberto Bosi,
Abstract Abstract 3558 Poster Board III-495 We recently reported in a pilot study, including 19 adult and pediatric patients affected by refractory cGvHD with fibrotic features, that the administration of Imatinib at low dose was well tolerated and effective, achieving an overall response rate (ORR) of 79% at 6 months; the response has been evaluated according to the modified Curiel Criteria. We report here the preliminary results of an Italian GITMO Multicenter study, aimed to confirm these promising ...
Tópico(s): Immunodeficiency and Autoimmune Disorders
2009 - Elsevier BV | Blood
Gianluca Cavallaro, Anna Grassi, Chiara Pavoni, Maria Caterina Micò, Alessandro Busca, Irene Cavattoni, Stella Santarone, Carlo Borghero, Attilio Olivieri, Giuseppe Milone, Patrizia Chiusolo, Pellegrino Musto, Riccardo Saccardi, Francesca Patriarca, Fabrizio Pane, Giorgia Saporiti, Paolo Rivela, Elisabetta Terruzzi, Raffaella Cerretti, Giuseppe Marotta, Angelo Michele Carella, Arnon Nagler, Domenico Russo, Paolo Corradini, Paolo Bernasconi, Anna Paola Iori, Luca Castagna, Nicola Mordini, Elena Oldani, Carmen Di Grazia, Andrea Bacigalupo, Alessandro Rambaldi,
We report the long-term results of a randomized trial (GITMO, AML-R2), comparing 1:1 the combination of busulfan and cyclophosphamide (BuCy2, n = 125) and the combination of busulfan and fludarabine (BuFlu, n = 127) as conditioning regimen in acute myeloid leukemia patients (median age 51 years, range 40-65) undergoing allogeneic hematopoietic stem cell transplantation. With a median follow-up of 6 years, significantly better non-relapse mortality (NRM) was confirmed in BuFlu recipients, which is sustained ...
Tópico(s): Acute Lymphoblastic Leukemia research
2024 - Springer Nature | Blood Cancer Journal
Gianluca Cavallaro, Anna Grassi, Chiara Pavoni, Maria Caterina Micò, Alessandro Busca, Irene Cavattoni, Stella Santarone, Carlo Borghero, Attilio Olivieri, Giuseppe Milone, Patrizia Chiusolo, Pellegrino Musto, Riccardo Saccardi, Francesca Patriarca, Fabrizio Pane, Giorgia Saporiti, Paolo Rivela, Elisabetta Terruzzi, Raffaella Cerretti, Giuseppe Marotta, Angelo Michele Carella, Arnon Nagler, Domenico Russo, Paolo Corradini, Paolo Bernasconi, Anna Paola Iori, Luca Castagna, Nicola Mordini, Elena Oldani, Carmen Di Grazia, Andrea Bacigalupo, Alessandro Rambaldi,
Background In a previous randomized trial performed by the Gruppo Italiano Trapianto di Midollo Osseo in AML patients (GITMO, AML-R2 study, Clinical Trial.gov number NCT01191957, Rambaldi A et al.: Lancet Oncology, 2015), we compared the combination of busulfan (3.2 mg/kg/die for four days) and fludarabine (160 mg/sqm) (BuFlu) with the conventional combination of busulfan and cyclophosphamide (120 mg/kg) (BuCy2). In this study, 252 AML patients with a median age of 52, undergoing allogeneic transplantation ...
Tópico(s): Hematopoietic Stem Cell Transplantation
2022 - Elsevier BV | Blood